In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer

Published:2004-10-29 Issue:1 Volume:12 Page:12-18
ISSN:0929-1903
Container-title:Cancer Gene Therapy
language:en
Short-container-title:Cancer Gene Ther

Author:

Sudarshan Sunil,Holman David H,Hyer Marc L,Voelkel-Johnson Christina,Dong Jian-Yun,Norris James S

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/7700746.pdf

Reference27 articles.

1. Cookson MS, Herr HW, Zhang ZF, et al. The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol. 1997; 158: 62.

2. Herr HW . Natural history of superficial bladder tumors: 10 to 20-year follow-up of treated patients. World J Urol. 1997; 15: 84.

3. Suda T, Hashimoto H, Tanaka M, et al. Membrane Fas Ligand kills human peripheral blood T lymphocytes, soluble Fas Ligand blocks the killing. J Exp Med. 1997; 186: 2045.

4. Suda T, Nagata S . Purification characterization of the Fas-ligand that induces apoptosis. J Exp Med. 1994; 179: 873.

5. Boldin MP, Varfolomeev EE, Pancer Z, et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem. 1995; 270: 7795.

Cited by 40 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genetic Modulation of Anticancer Drugs Affecting Pharmacokinetic for Safety and Efficacy;Handbook of Oncobiology: From Basic to Clinical Sciences;2024

2. Lipid-based Nanoparticles (LNP) Structures used for Drug Delivery and Targeting: Clinical Trials and Patents;Nanoscience & Nanotechnology-Asia;2023-10

3. CD95/Fas ligand induced toxicity;Biochemical Society Transactions;2023-01-11

4. Genetic Modulation of Anticancer Drugs Affecting Pharmacokinetic for Safety and Efficacy;Handbook of Oncobiology: From Basic to Clinical Sciences;2023

5. Therapeutic approaches targeting CD95L/CD95 signaling in cancer and autoimmune diseases;Cell Death & Disease;2022-03-17

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3